Kolon Tissuegene, Inc.
Records under this name other than the patents Kolon Tissuegene, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
Showing 1 to 6 of 6 · Back to Kolon Tissuegene, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,431,922 | Bioadhesive directed somatic cell therapy Term ended Term ended Feb 27, 2024 · USPTO record | Term ended | Term ended Feb 27, 2024 | USPTO record |
| US 7,005,127 | Mixed-cell gene therapy Term ended Term ended Sep 25, 2023 · USPTO record | Term ended | Term ended Sep 25, 2023 | USPTO record |
| US 7,282,200 | Mixed-cell gene therapy Term ended Ended no later than Mar 5, 2023 · USPTO record | Term ended | Ended no later than Mar 5, 2023 | USPTO record |
| US 6,315,992 | Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-.beta.-1 Term ended Term ended Jun 30, 2019 · USPTO record | Term ended | Term ended Jun 30, 2019 | USPTO record |
| US 6,797,703 | Gene therapy using TGF-&bgr; Term ended Term ended Jun 30, 2019 · USPTO record | Term ended | Term ended Jun 30, 2019 | USPTO record |
| US 7,338,655 | Gene therapy using TGF-β Term ended Ended no later than Jun 30, 2019 · USPTO record | Term ended | Ended no later than Jun 30, 2019 | USPTO record |